BeStock  
Stocks › Biotechnology › BLTE

Belite Bio BLTE

US equityMarket cap rank #2018Biotechnology
$127.38 −$23.64 (-15.65%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $127.38 0.00%
Open$129.00
Prev close$151.02
Day range$120.00 – $135.07
Volume1.04M
Market cap$5.17B
P/E (TTM)–
Dividend yield–

BLTE Stock News

Headlines matching Belite Bio or the BLTE ticker, most recent first.

  • Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234 PositiveMarket news · 9 Sep 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)TipRanks · 9 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245Market news · 9 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245 PositiveMarket news · 8 Sep 2026 · Direct mention
  • Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220Market news · 6 Sep 2026 · Direct mention
  • CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303Market news · 4 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214Market news · 3 Sep 2026 · Direct mention
  • BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200Market news · 3 Sep 2026 · Direct mention
  • Belite Bio(BLTE.US) Officer Sells US$12.8 Million in Common StockMarket news · 10 Sep 2026 · Direct mention
  • Belite Bio(BLTE.US) Officer Sells US$19.08 Million in Common StockMarket news · 10 Sep 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)TipRanks · 31 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206 PositiveMarket news · 17 Aug 2026 · Direct mention
  • Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200Market news · 16 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)TipRanks · 16 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)TipRanks · 15 Aug 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on BLTE.

Sign in to join the discussion.

Scroll to Top